Project Oncology®

What are the current treatment options available for paroxysmal nocturnal hemoglobinuria (PNH), and how can we select the appropriate option based on various factors like efficacy, safety, and patient access? Joining Dr. Charles Turck in this important discussion is Dr. Brian Mulherin from Hematology Oncology of Indiana and Ascension St. Vincent Hospital in Indianapolis.

The goal of a clinician who is working with a patient who has paroxysmal nocturnal hemoglobinuria (PNH) is to improve their overall quality of life. So what approach can we use to address suboptimal patient outcomes? Join Dr. Charles Turck as he guides us through this PNH journey with Dr. David Dingli, Professor of Medicine in the Department of Hematology at the Mayo Clinic Comprehensive Cancer Center in Rochester, Minnesota.

While key clinical trials inform our management philosophy for patients with recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN), the paucity of predictive markers, limited guidance to treatment sequencing, and inherent therapeutic toxicity provide challenges for both clinicians and patients. How can we best stratify our patients to ensure the most optimal outcomes? Join Drs. Ezra Cohen and Petr Szturz as they offer cogent answers to the difficult questions you face in your daily medical practice.

For patients with ER+/HER2- advanced breast cancer, current treatment guidelines recommend the use of endocrine therapy plus a CDK 4/6 inhibitor as a first-line treatment. And while the guidelines recommend sequential endocrine therapy for disease progressions, this progression can lead to ESR1 mutations and resistance to endocrine therapy. Could a novel oral selective estrogen receptor have more efficacy in preventing ESR1 mutations associated with endocrine resistance? That’s the exact question the EMERALD trial sought to answer, and what this study found in its subgroup analyses is the focus of this Audio Abstract.

Results from a recent study detail the impact that fungi can have in human cancer tumors. What do we need to know? Mario Nacinovich speaks with one of the researchers, Dr. Gregory Sepich-Poore from UC San Diego, to dive further into these results and their impact on cancer therapeutics.

Can multi-cancer early detection (MCED) tests potentially lead to a reduction in the number of people who die from the disease by improving screening rates and extending screening for cancers without standard screening today? So what do we need to know about these tests? To discuss this more in-depth, Dr. Charles Turck is joined by Dr. Tomasz Beer, Chief Medical Officer for Multi-Cancer Early Detection at Exact Sciences Corporation and Adjunct Professor of Medicine at the OHSU Knight Cancer Institute.

© 2022 Exact Sciences Corporation. All rights reserved.
US.CAG.00020.HCP 12/22

Given the challenges and unmet needs associated with the current treatment options for ER+/HER2- advanced breast cancer, what strategies can we use to optimize our approach? Here with Dr. Jennifer Caudle to share their perspectives are Dr. Stephania Graff from Lifespan Cancer Institute and Dr. Pavani Chalasani from the University of Arizona Cancer Center.

What do we need to know about the therapeutic landscape and management of myelofibrosis-related anemia? Here to share their perspectives with Dr. Charles Turk are Dr. Raajit Rampal from the Memorial Sloan Kettering Cancer Center and Dr. John Mascarenhas from Mount Sinai.

Endocrine therapy is the recommended treatment for ER+/HER2- advanced breast cancer, but progression to advanced disease can lead to ESR1 mutations, which can then lead to endocrine therapy resistance. But could treatment with an oral selective estrogen receptor degrader (SERD) improve outcomes for our patients? Join us as we take a deep dive into the EMERALD trial, which explored that exact question, in this Audio Abstract.

Selective estrogen receptor degraders (SERDs) are a novel class of drugs for the treatment of ER+/HER2- advanced breast cancer. So how exactly do they work to treat this type of advanced breast cancer, and what are the findings from recent trials investigating the clinical utility of SERDs? Get the answers to these and other key questions with Dr. Jennifer Caudle and Dr. Nan Chen, Assistant Professor of Medicine at the University of Chicago School of Medicine.